GSK3179106 is an investigational compound developed for its potential therapeutic use in neurological and psychiatric disorders. It acts as a selective agonist of the metabotropic glutamate receptor 2 (mGlu2), which plays a role in modulating glutamatergic neurotransmission—a key pathway implicated in conditions such as schizophrenia and anxiety disorders. The primary application of GSK3179106 lies in its evaluation as an antipsychotic agent. By activating mGlu2 receptors, it helps regulate excessive glutamate activity in the brain, which is thought to contribute to psychotic symptoms. This mechanism offers a novel approach compared to traditional dopamine receptor-blocking antipsychotics, potentially providing efficacy with fewer motor side effects. It has been studied in clinical trials for the treatment of schizophrenia, particularly in patients who may not respond adequately to current therapies. Additionally, its glutamate-modulating effects are being explored in anxiety-related conditions where conventional treatments have limitations. Due to its targeted mechanism, GSK3179106 represents a step toward more personalized and mechanism-based treatments in neuropsychiatry, although it remains under investigation and is not yet approved for routine clinical use.